HealthEquity Inc. (HQY)
HealthEquity, Inc. (HQY) Q2 2025 Earnings Call Transcript
HealthEquity, Inc. (NASDAQ:HQY ) Q2 2025 Earnings Conference Call September 3, 2024 4:30 PM ET Company Participants Richard Putnam - IR Jon Kessler - President & CEO James Lucania - EVP & CFO Steve Neeleman - Vice Chair and Founder Conference Call Participants Anne Samuel - J.P. Morgan Glen Santangelo - Jefferies Sean Dodge - RBC Capital Markets Stan Berenshteyn - Wells Fargo Securities Allen Lutz - Bank of America Scott Schoenhaus - KeyBanc David Larsen - BTIG Stephanie Davis - Barclays Mark Marcon - Baird George Hill - Deutsche Bank Operator Good afternoon and welcome to the HealthEquity Second Quarter 2025 Earnings Conference Call.
HealthEquity (HQY) Reports Q2 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for HealthEquity (HQY) give a sense of how the business performed in the quarter ended July 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
HealthEquity (HQY) Surpasses Q2 Earnings and Revenue Estimates
HealthEquity (HQY) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.70 per share. This compares to earnings of $0.53 per share a year ago.
What Analyst Projections for Key Metrics Reveal About HealthEquity (HQY) Q2 Earnings
Evaluate the expected performance of HealthEquity (HQY) for the quarter ended July 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
HealthEquity: A Checkup As We Head Into Earnings
HealthEquity, a provider of HSAs and CDBs, has shown strong growth and improved cash flows, leading me to upgrade it to a 'buy' in May. Despite a 2.9% drop in shares versus a 6.5% rise in the S&P 500, I remain confident in HealthEquity's long-term potential. Recent financials show impressive growth: Q1 revenue up 17.7%, net income surged from $4.1M to $28.8M, and EBITDA increased from $86.6M to $117.4M.
Is HealthEquity Stock a Hold Now Amid Strong Top-Line Growth?
HQY's sustained strength in HSAs raises optimism about the stock.
HealthEquity: Compelling Catalysts, Fairly Valued, Reiterate Buy
HealthEquity continues to present highly attractive fundamentals. FY'25 is guidance raised to ~$1.18Bn in revenue and ~$3.10/share in earnings. Technicals are robust on longer-term time frames, with price structure strengthening after demand-fill at ~$55-$60s.
Here's Why HealthEquity (HQY) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
INVESTIGATION ALERT: Levi & Korsinsky, LLP Investigates HealthEquity, Inc. (NASDAQ: HQY) Data Breach
NEW YORK, NY / ACCESSWIRE / August 14, 2024 / HealthEquity, Inc. ("HealthEquity") has disclosed a data breach affecting the personal information of its customers. The breach compromised sensitive personal information entrusted to HealthEquity.
HealthEquity, Inc. (NASDAQ: HQY) Data Breach - Levi & Korsinsky, LLP Announces an Investigation
NEW YORK, NY / ACCESSWIRE / August 13, 2024 / HealthEquity, Inc. ("HealthEquity") has disclosed a data breach affecting the personal information of its customers. The breach compromised sensitive personal information entrusted to HealthEquity.
ATA BREACH: HealthEquity, Inc. (NASDAQ:HQY) Investigated by Levi & Korsinsky, LLP
NEW YORK, NY / ACCESSWIRE / August 12, 2024 / HealthEquity, Inc. ("HealthEquity") has disclosed a data breach affecting the personal information of its customers. The breach compromised sensitive personal information entrusted to HealthEquity.
Levi & Korsinsky, LLP Investigates HealthEquity, Inc. (NASDAQ: HQY) in Connection with Recent Data B
NEW YORK, NY / ACCESSWIRE / August 9, 2024 / HealthEquity, Inc. ("HealthEquity") has disclosed a data breach affecting the personal information of its customers. The breach compromised sensitive personal information entrusted to HealthEquity.
